Related Experiment Video
Updated: Jul 28, 2025
Reconstruct Human Retinoblastoma In Vitro
Published on: October 11, 2022
Clinical analysis of 2790 children with retinoblastoma: a single-center experience in China
Yi Zhang1, Yi-Zhuo Wang1, Ji-Tong Shi2
1Department of Pediatrics, Beijing Tongren Hospital, Capital Medical University, Beijing 100176, China.
Insights
This study analyzed 2790 children with retinoblastoma (RB), finding that timely treatment and enucleation are crucial for improving prognosis. Advanced diagnosis and treatment technologies are essential for better outcomes in pediatric RB patients.
Area of Science:
- Ophthalmology
- Pediatric Oncology
- Clinical Genetics
Background:
- Retinoblastoma (RB) is a significant pediatric eye cancer.
- Understanding clinical characteristics and prognosis is vital for treatment strategies.
- A large-scale, long-term study provides valuable insights into RB in China.
Purpose of the Study:
- To analyze the clinical characteristics of retinoblastoma (RB) in children.
- To evaluate the prognosis of pediatric RB patients.
- To identify factors influencing RB outcomes in a Chinese cohort.
Main Methods:
- Retrospective analysis of 2790 pediatric RB cases.
- Data collected from Beijing Tongren Hospital (2005-2021).
- Kaplan-Meier and Cox multivariate survival analyses performed.
Main Results:
- Median age was 28.3 months; 67.1% of eyes were in advanced stages (D-E).
- White pupil (66.5%) and strabismus (12.8%) were primary symptoms.
- Overall survival rate was 95.8%; trilateral RB and metastasis were independent poor prognostic factors.
Conclusions:
- Optimal timing for eye-saving treatment and enucleation is critical.
- Delayed operations can worsen prognosis.
- Promoting advanced diagnosis and treatment technologies is necessary to improve pediatric RB outcomes.
Background:
In this study, we aimed to analyze the clinical characteristics and prognosis of children with retinoblastoma (RB) in a single center in China with a large sample collection spanning 17 years.
Methods:
The clinical data of 2790 children with RB treated in Beijing Tongren Hospital from 2005 to 2021 were collected, and a retrospective analysis was conducted.
Results:
The median age of the participants was 28.3 months. There were 3624 affected eyes, 12.4% of which were in groups A-C, 67.1% in groups D-E and 16.2% were not specified. The primary symptom observed in most cases was a white pupil, accounting for 66.5%, followed by strabismus (12.8%). The median follow-up time was 59.7 months. The enucleation rate was 71.3% (703/986) in a single left eye and 72.5% (702/968) in a single right eye. The overall survival (OS) rate was 95.8% (2444/2552) because 237 patients dropped out, and 109 died. Kaplan‒Meier survival analysis showed that the median survival time (MST) was 125.92 months [95% confidence interval (CI) = 124.83-127.01]. Cox multivariate survival analysis showed that trilateral RB (P = 0.017), metastasis site (P = 0.001), and combined distant tissue metastasis (P = 0.001) were independent prognostic factors for RB. The OS of 44 cases of familial RB was 93.2% (41/44), with an MST of 80.62 months (95% CI = 67.70-93.54).
Conclusions:
The timing of eye protection treatment and enucleation should be comprehensively judged to avoid worsening prognosis due to operation time delay. More importantly, the promotion and popularization of diagnosis and treatment technologies are necessary to further improve RB prognosis.
